EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States

Kathryn Lurain, Talal El Zarif, Ramya Ramaswami, Amin H Nassar, Elio Adib, Noha Abdel-Wahab, Nikita Chintapally, Claire E Drolen, Tatyana Feldman, Tarek Haykal, Caroline A Nebhan, Swetha Kambhampati Thiruvengadam und 18 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.03.011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Kathryn Lurain und 29 weiteren Autor:innen. Beteiligte Einrichtung: HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic addres…. Hauptthemen laut MEDLINE: Hodgkin Disease, HIV Infections, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on the use of these agents in HIV-associated cHL (HIV-cHL). PATIENTS/METHODS: We retrospectively identified patients with HIV-cHL from the "Cancer Therapy using Checkpoint inhibitors in People with HIV-International (CATCH-IT)" database who received nivolumab or pembrolizumab, alone or in combination with other agents, and reviewed records for demographics, disease characteristics, immune-mediated adverse events (imAEs), and treatment outcomes. Changes in CD4+ T-cell counts with treatment were measured via Wilcoxon signed-rank tests. Overall response rate (ORR) was defined as the proportion of patients with partial or complete response (PR/CR) per 2014 Lugano classification. RESULTS: We identified 23 patients with HIV-cHL who received a median of 6 cycles of PD-1 blockade: 1 as 1st-line, 6 as 2nd-line, and 16 as ≥3rd-line therapy. Seventeen (74%) patients received monotherapy, 5 (22%) received nivolumab plus brentuximab vedotin, and 1 received nivolumab plus ifosfamide, carboplatin, and etoposide. The median baseline CD4+ T-cell count was 155 cells/µL, which increased to 310 cells/µL at end-of-treatment (P = .009). Three patients had grade 3 imAEs; none required treatment discontinuation. The ORR was 83% with median duration of response of 19.7 months. The median progression-free survival was 21.2 months and did not differ between patients with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHIV InfectionsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesUnited StatesNivolumabProgrammed Cell Death 1 ReceptorAgedTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Anti-PD-1Checkpoint inhibitorsHIV/AIDS

Substanzen

Immune Checkpoint InhibitorsNivolumabProgrammed Cell Death 1 ReceptorpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: kathryn.lurain@nih.gov.
  • Yale University School of Medicine, New Haven, CT.
  • HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Brigham and Women's Hospital, Department of Radiation Oncology, Boston, MA.
  • MD Anderson Cancer Center, Houston, TX.
  • Medstar/Georgetown-Washington Hospital Center, Washington, DC.

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • Intramural NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Lurain, K., Zarif, T. E., Ramaswami, R., Nassar, A. H., Adib, E., Abdel-Wahab, N., Chintapally, N., Drolen, C. E., Feldman, T., Haykal, T., Nebhan, C. A., Thiruvengadam, S. K., Li, M., Mittra, A., Lorentsen, M., Kim, C., Drakaki, A., Morse, M., Johnson, D. B., …, & Herrera, A. F. (2024). Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.03.011

Vancouver

Lurain K, Zarif TE, Ramaswami R, Nassar AH, Adib E, Abdel-Wahab N, et al. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.03.011

BibTeX
@article{Lurain2024,
  author = {Lurain, Kathryn and Zarif, Talal El and Ramaswami, Ramya and Nassar, Amin H and Adib, Elio and Abdel-Wahab, Noha and Chintapally, Nikita and Drolen, Claire E and Feldman, Tatyana and Haykal, Tarek and Nebhan, Caroline A and Thiruvengadam, Swetha Kambhampati and Li, Mingjia and Mittra, Arjun and Lorentsen, Michael and Kim, Chul and Drakaki, Alexandra and Morse, Michael and Johnson, Douglas B and Mangla, Ankit and Dittus, Christopher and Ravi, Praful and Baiocchi, Robert A and Chiao, Elizabeth Y and Rubinstein, Paul G and Yellapragada, Sarvari V and LaCasce, Ann S and Sonpavde, Guru P and Naqash, Abdul Rafeh and Herrera, Alex F},
  title = {Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.03.011}
}
Kostenlos starten →